Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8469-8476

  Cadieux, Benoît ^a   Ching, Tsui Ting ^a,c   VandenBerg, Scott R ^a,b   Costello, Joseph F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLCYTOSINE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CANCER TESTIS ANTIGEN; DINUCLEOTIDE; MELANOMA ANTIGEN 1; SATELLITE DNA; VALINE;

ALLELE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMOSOME 1; CHROMOSOME 10Q; CHROMOSOME 16; CHROMOSOME 4Q; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; EUCHROMATIN; GENE DELETION; GENOME ANALYSIS; GLIOBLASTOMA; GLIOMA; HAPLOIDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSPERSED REPEAT; METHYLATION; MUTATION; PRIORITY JOURNAL;

5-METHYLCYTOSINE; BRAIN NEOPLASMS; CELL DIVISION; DNA METHYLATION; DNA, NEOPLASM; GENOME, HUMAN; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); SEQUENCE DELETION;

EID: 33749039999     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1547     Document Type: Article

References (50)

1. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol 2000;27:1-10.
2. Misra A, Pellarin M, Nigro J, et al. Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 2005;11:2907-18.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
5. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983;11:6883-94.
6. Rollins RA, Haghighi F, Edwards JR, et al. Large-scale structure of genomic methylation patterns. Genome Res 2006;16:157-63.
7. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis-epigenetics joins genetics. Trends Genet 2000;16:168-74.
8. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
9. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
10. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10:3001-7.
11. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
12. Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004;64:5527-34.
13. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92.
14. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.
15. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.
16. Karpf AR, Matsui S. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 2005;65:8635-9.
17. Holm TM, Jackson-Grusby L, Brambrink T, et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005;8:275-85.
18. Prak ET, Kazazian HH, Jr. Mobile elements and the human genome. Nat Rev Genet 2000;1:134-44.
19. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
20. Narayan A, Ji WZ, Zhang XY, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998;77:833-8.
21. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-β 2 gene in breast cancer. J Natl Cancer Inst 2000;92:826-32.
22. Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 2003;109:17-28.
23. Qu GZ, Dubeau L, Narayan A, Yu MC, Ehrlich M. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 1999;423:91-101.
24. Wong N, Lam WC, Lai PB, et al. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol 2001;159:465-71.
25. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
26. De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 1996;93:7149-53.
27. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) 2004;229:988-95.
28. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease-a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
29. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002;99:5606-11.
30. Heijmans BT, Boer JM, Suchiman HE, et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 2003;63:1249-53.
31. Beilby J, Ingram D, Hahnel R, Rossi E. Reduced breast cancer risk with increasing serum folate in a case-control study of the C677T genotype of the methylenetetrahydrofolate reductase gene. Eur J Cancer 2004;40:1250-4.
32. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999;96:12810-5.
33. Bariol C, Suter C, Cheong K, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003;162:1361-71.
34. Ehrlich M, Gama-Sosa MA, Huang L-H, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues and cells. Nucleic Acids Res 1982;10:2709-21.
35. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999;19:7327-35.
36. Cheung VG, Nowak N, Jang W, et al. Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature 2001;409:953-8.
37. Jackson K, Yu MC, Arakawa K, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004;3:1225-31.
38. Gama-Sosa MA, Wang RY, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of highly repeated sequences in human DNA. Nucleic Acids Res 1983;11:3087-95.
39. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000;15:835-42.
40. van Overveld PG, Enthoven L, Ricci E, et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol 2005;58:569-76.
41. Vatolin S, Abdullaev Z, Pack SD, et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005;65:7751-62.
42. Loukinov DI, Pugacheva E, Vatolin S, et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 2002;99:6806-11.
43. Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004;64:4980-6.
44. Scarcella DL, Chow CW, Gonzales MF, et al. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999;5:335-41.
45. Eramo A, Pallini R, Lotti F, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 2005;65:11469-77.
46. Gloria L, Cravo M, Pinto A, et al. DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. Cancer 1996;78:2300-6.
47. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
48. McCabe MT, Low JA, Daignault S, et al. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006;66:385-92.
49. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62.
50. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.